[Heparin-induced thrombocytopenia].
Research article published in Der Internist (2010)
Abstract
Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction that carries an increased risk of thromboembolic complications. HIT is caused by platelet-activating antibodies directed against a complex of platelet factor 4 (PF4) and heparin. HIT typically manifests in the second week after initiation of heparin therapy with a platelet count reduction of more than 50% of the highest level after the start of heparin administration as well as thromboembolic events. The clinical probability can be calculated by the 4 T's score. The laboratory diagnosis of HIT is based on confirmation of PF4/heparin antibodies or on functional tests that provide evidence of heparin-dependent platelet-activating antibodies. A low 4 T's score and negative HIT test virtually rule out the presence of HIT. Patients with acute HIT require anticoagulation with a compatible anticoagulant in a therapeutic dose. The drugs currently available for this include the direct thrombin inhibitors argatroban, lepirudin, bivalirudin, and desirudin and the indirect factor Xa inhibitors danaparoid and fondaparinux.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
[Heparin-induced thrombocytopenia].
Why This Matters for Hirudotherapy
This review article describes heparin-induced thrombocytopenia (HIT)—an adverse drug reaction caused by platelet-activating antibodies against platelet factor 4/heparin complexes, presenting with thrombocytopenia and thromboembolic events—and outlines its diagnosis via the 4T's clinical scoring system, laboratory antibody/functional testing, and pharmacologic management. Notably, the anticoagulants listed for acute HIT include lepirudin, desirudin, and bivalirudin, which are recombinant forms or analogs of hirudin, the signature anticoagulant of the medicinal leech secretome, giving the article direct and defensible relevance to ASH and hirudotherapy. The discussion underscores how leech-derived anticoagulant pharmacology continues to inform mainstream clinical management of thrombotic complications. An honest caveat is that this is a narrative clinical review of HIT management rather than original research on leech therapy itself; it does not provide primary efficacy or safety data for hirudotherapy.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026